Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study

Blood

Volumn 98, Issue 12, 2001, Pages 3212-3220

  List, Alan F ^a   Kopecky, Kenneth J ^a   Willman, Cheryl L ^a   Head, David R ^a   Persons, Diane L ^a   Slovak, Marilyn L ^a   Dorr, Robert ^a   Karanes, Chatchada ^a   Hynes, Harry E ^a   Doroshow, James H ^a   Shurafa, Muhammad ^a   Appelbaum, Frederick R ^a  

^a Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DAUNORUBICINOL; GLYCOPROTEIN P;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 0035760302     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.12.3212     Document Type: Article

References (56)

1. Gerlach JH, Endicott JA, Juranka PF, et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature. 1986;324:485-489.
2. Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V. Identification of members of the P-glycoprotein multigene family. Mol Cell Biol. 1989;9:1224-1232.
3. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987;84:3004-3008.
4. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Overexpression of the mdr 1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer. 1990;45:263-268.
5. Coley HM, Twentyman PR, Workman P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol. 1989;38:4467-4475.
6. Naito M,Tsuge H, Kuroko C, et al. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Natl Cancer Inst. 1993;85:311-316.
7. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991;83:708-712.
8. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression in acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992;79:473-476.
9. List AF, Spier CM, Cline A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol. 1992;78:28-34.
10. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997;89:3323-3329.
11. Samdani A, Vijapurkar U, Grimm MA, et al. Cytogenetics and P-glycoprotein (Pgp) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res. 1996;20:175-180.
12. List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996;10:937-942.
13. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol. 1993;11:1652-1160.
14. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994;12:835-842.
15. Cheson BD, Cassileth PS, Head DR, et al. Report of the National Cancer Institute-sponsored workshop of definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
16. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1995;31:103-115.
17. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253.
18. - cases. Blood. 1995;86:2329-2342.
19. Young IT. Proof without prejudice: Use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem. 1977;25:935-941.
20. Peng YM, Alberts DS, Salmon SE, Davis TP. A method for the simultaneous measurement of the new anthracycline derivative 4′-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography. Invest New Drugs. 1984;2:277-280.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
22. Mitelman F (ed). An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
23. Schiffer CA, Lee Ej, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263-270.
24. Fenaux P, Preudhomme C, Lai JL, Morel P, Beauscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report on 283 cases. Br J Haematol. 1989;73:61-67.
25. Slovak ML, Kopecky KJ, Cassileth PA, et al for the Southwest Oncology and Eastern Oncology Cooperative Groups. Karyotypic analysis predicts outcome of pre- and post-remission therapy in adult acute myeloid leukemia (AML): a SWOG/ECOG intergroup study. Blood. 2000;96:4075-4083.
26. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult myeloid leukemia. Leukemia. 1995;9:1491-1498.
27. Cox DR. The Analysis of Binary Data. London, United Kingdom: Chapman & Hall; 1970.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
29. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
30. Kornblau SM, Estey E, Madden T, et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol. 1997;15:1796-1802.
31. Booth CL, Brouwer KR, Brouwer KL. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res. 1998;58:3641-3648.
32. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol. 1992;10:1635-1642.
33. Cass CE, Janowska-Wieczorek A, Lynch MA, et al. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines. Cancer Res. 1989;49:5798-4804.
34. Lai GM, Chen YN, Mickley LA, et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696-703.
35. Slate D, Michelson S. Drug resistance-reversal strategies: comparison of experimental data with model predictions. J Natl Cancer Inst. 1991;83:1574-1580.
36. Toffoli G, Tumiotto L, Gigante M, et al. Increased chemosensitivity to doxorubicin of intrinsically multidrug resistant human colon carcinoma cells by prolonged exposure to verapamil. Eur J Cancer. 1993;29A:1776-1778.
37. Solary E, Witz B, Caillot D, et al. Combination of quinine as a reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood. 1996;88:1198-1205.
38. Liu Tin JA, Wheatley K, Rees J, Burnett A. Comparison of two chemotherapy regimens with or without cyclosporine-A, in relapsed/refractory acute myeloid leukemia.: results of the UK Medical Research Council AML-R trial [abstract]. Blood. 1998;92:231a.
39. Politit PM, Arnold ST, Felsted RL, Sinha BK. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Mol Pharmacol. 1990;37:790-796.
40. Sehested M, Friche E, Jensen PB, Demant EJF. Relationship of VP-16 to the classical multidrug resistance phenotype. Cancer Res. 1992;52:2874-2879.
41. Greenberg P, Advani R, Tallman M, et al. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: randomized phase II trial (E2995) [abstract]. Blood. 1999;94:383a.
42. Baer MR, George SL, Dodge RK, et al. Phase III study of PSC833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients years (CALGB 9720) [abstract]. Blood. 1999;94:383a.
43. Dorr R, Karanes C, Spier C, et al. Phase I/Il study of the p-glycoprotein modulator PSC 833 (valspodar) in patients with acute myeloid leukemia. J Clin Oncol. 2000. In press.
44. Ross DD, Wooten PJ, Tong Y, et al. Synergistic reversal of multidrug resistance phenotype in acute myeloid leukemia cells by cyclosporin A and Cremophor EL. Blood. 1994;83:1337-1347.
45. Ross DD, Wooten PJ, Sridhara R, et al. Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood. 1993;82:1288-1299.
46. Cole SPC, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994;54:5902-5910.
47. Doyle LA, Ross D, Sridhara R, et al. Expression of a 95 kDa membrane protein is associated with low daunorubicin retention in leukemic blast cells. Br J Cancer. 1995;71:52-58.
48. Doyle LA, Tang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95:15665-15670.
49. Iurlaro M, Vacca A, Minischetti M, et al. Antiangiogenesis by cyclosporine. Exp Hematol. 1998;26:1215-1222.
50. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor (VEGF) is an autocrine promoter of abnormal localized immature myeloid precursors (ALIP) and leukemia progenitor formation in myelodysplastic syndromes (MDS). Blood. 2001;97:1427-1434.
51. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870-1875.
52. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721.
53. Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporin-A reverses vincristine and daunorubicin resistance in acute lymphoblastic leukemia in vitro. J Clin Invest. 1986;77:1405-1408.
54. Meador J, Sweet P, Stupecky M, et al. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. Cancer Res. 1987;47:6216-6219.
55. Ito C, Ribeiro RC, Behm FG, Raimondi SC, Pui CH, Campana D. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood. 1998;91:1001-1007.
56. List AF, Glinsmann-Gibson, Heaton R, Schlegel S, Guzman M, Futscher B. Cyclosporines (CS) inhibit interleukin-1β (L-1β) secretion by the ABC-1 transporter, impair leukemia self-renewal and sensitize AML progenitors to antineoplastics [abstract]. Blood. 1998;92:675a.